This content is intended for healthcare professionals outside the USA only.

Please confirm that you are a healthcare professional outside the USA.

Decline

This activity has been sponsored by Novartis Pharma AG. Novartis Pharma AG provided financial support and has had input into the selection of the faculty and/or the detailed project scope.  This activity is provided by Touch Medical Communications (TMC) for touchOPHTHALMOLOGY.

Macular Degeneration Watch Time: 20 mins

touchJOURNAL CLUB HAWK and HARRIER: Ninety-Six-Week Outcomes from the Phase III Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration

The burden of neovascular age-related macular degeneration (nAMD) remains high in real world clinical practice, and new treatments are needed to improve outcomes and reduce the amount of clinic visits.

Now Playing:
Up Next:
 
Prof. Armin Wolf
Medical Director, Ulm University Hospital, Ophthalmology, Germany
Design and outcomes of the HAWK and HARRIER trials

Armin Wolf gives an overview of the 96-week data from the HAWK and HARRIER trials, including the study designs, efficacy, anatomical and functional outcomes, as well as the safety profile of brolucizumab in these trials.

1/3 Next Interview
Leave Feedback
Interview Questions

In this interview we asked Prof. Wolf the following questions:

  • What were the overall intentions of the HAWK and HARRIER trials?
  • What were the key design features of the HAWK and HARRIER trials?
  • What was the primary endpoint, and in your opinion, what were the most impactful outcomes of the HAWK and HARRIER trials?
  • What were the anatomical and functional outcomes of the HAWK and HARRIER trials?
  • What was the safety profile of brolucizumab in the HAWK and HARRIER trials?
About Prof. Armin Wolf

After graduating from high school, Armin Wolf studied human medicine at the Friedrich Schiller University in Jena, the Universidad Autónoma in Barcelona and the Ludwig Maximilians University in Munich. In 2007 he successfully completed his specialist training and doctorate at the Ludwig Maximilians University Clinic and then worked as a senior physician.

In 2010 Prof. Wolf took over as the Deputy Head of the intraocular surgery division, under Prof. Anselm Kampik. From 2014, Prof. Wolf held the position of Deputy Director of the Eye Clinic at the University of Munich Hospital, until he moved to his current position at the Ulm University Hospital.

Disclosures:
Consultant/ Speaker fees from: Novartis

 
Prof. Armin Wolf
Medical Director, Ulm University Hospital, Ophthalmology, Germany
How the HAWK and HARRIER trials inform daily clinical practice

Armin Wolf highlights the importance of treating fluid to preserve vision in patients with nAMD, and gives his thoughts on the optimal functional, anatomical and safety assessments during treatment. He also comments on his experience with brolucizumab, particularly in the context of the current pandemic.

2/3 Next Interview
Leave Feedback
Interview Questions

In this interview we asked Prof. Wolf the following questions:

  • Why do you think it is important to treat fluid or dry the retina?
  • How should clinicians initiate and maintain treatment with brolucizumab for nAMD?
  • How should clinicians perform functional and anatomical assessments of disease activity in their patients with nAMD?
  • How should clinicians approach safety monitoring and intervention in their patients with nAMD receiving brolucizumab?
  • How relevant is imaging for monitoring IOI and managing patients with nAMD?
  • How has the treatment interval for brolucizumab been beneficial during the current COVID-19 pandemic?
About Prof. Armin Wolf

After graduating from high school, Armin Wolf studied human medicine at the Friedrich Schiller University in Jena, the Universidad Autónoma in Barcelona and the Ludwig Maximilians University in Munich. In 2007 he successfully completed his specialist training and doctorate at the Ludwig Maximilians University Clinic and then worked as a senior physician.

In 2010 Prof. Wolf took over as the Deputy Head of the intraocular surgery division, under Prof. Anselm Kampik. From 2014, Prof. Wolf held the position of Deputy Director of the Eye Clinic at the University of Munich Hospital, until he moved to his current position at the Ulm University Hospital.

Disclosures:
Consultant/ Speaker fees from: Novartis

 
Prof. Anat Loewenstein
Professor of Ophthalmology and Vice Dean, Tel Aviv University, Israel
Brolucizumab in the treatment of patients with nAMD

Anat Loewenstein considers the implications of the HAWK and HARRIER 2-year data, and how these are likely to significantly change the management of nAMD, improve patient quality of life, and reduce the burden on healthcare systems.

3/3 Leave Feedback
Leave Feedback
Interview Questions

In this interview we asked Prof. Loewenstein the following questions:

  • In your opinion, what are the key learnings from the HAWK and HARRIER 2-year outcomes?
  • How do you think these results may change the management of patients with nAMD?
  • What are the implications of HAWK and HARRIER outcomes for fluid control and targeting sustained dryness in patients with nAMD?
  • How might the publication of 2-year outcomes data from the HAWK and HARRIER impact scheduling clinic visits for your patients with nAMD?
  • Which are the most relevant parameters to assess disease activity in the treatment of patients with nAMD receiving brolucizumab?
About Prof. Anat Loewenstein

Anat Loewenstein, MD, Full Professor of Ophthalmology, Vice Dean of the Faculty of Medicine, and Sidney Fox Chair of Ophthalmology at the Sackler Faculty of Medicine at the Tel Aviv University, and the Chairman of the Department of Ophthalmology at the Tel Aviv Medical Center.

Disclosures: Consultant/ Speaker fees from: Allergan, Bayer, Novartis, Notal–vision, Syneos Health, Beyeonics Surgical, Roche, Pres-By, Xbran, WebMD, KHB, Oxurion

Leave Feedback
Overview & Learning Objectives
Overview

Watch leading experts explain and discuss the 96-week outcomes from the Phase III HAWK and HARRIER trials comparing brolucizumab with aflibercept for the treatment of neovascular age-related macular degeneration (nAMD), and provide their thoughts on the implications of these data for clinical practice, patient outcomes, quality of life, and burden on healthcare systems during the current pandemic.

Learning Objectives

After watching this activity participants should be better able to:

  • Describe the design and outcomes of the HAWK and HARRIER trials
  • Discuss how the results of the HAWK and HARRIER trials inform daily clinical practice
  • Summarize the impact of brolucizumab on the management of patients with nAMD
References
References
  1. Dugel PU, et al. HAWK and HARRIER: Ninety-Six-Week Outcomes from the Phase 3 Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. Ophthalmology. 2021;128(1):89–99
Downloads

View and download resources from this activity to support your learning or share with colleagues.

Feedback Close
Feedback

Please provide feedback for this touchJOURNAL CLUB on the following
(scale 1-5, 1 strongly disagree; 5 strongly agree):

Feedback Close
Copied to clipboard!
accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72